November 1, 2016

Arrowhead Pharmaceuticals to Present at Upcoming Conferences

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events:

The 25th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016

November 7, 11:30 a.m. MST - Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation

The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - Boston, November 11-15, 2016

November 13, 5:30 p.m. EST - Christine Wooddell, Ph.D., Arrowhead director of liver targeting will deliver an oral presentation titled, "**RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model**"

November 13, 8:00 a.m. EST - Alice Turner, MBChB (Hons), MRCP, PGCE (MedEd), PhD, University of Birmingham, Edgbaston Birmingham, United Kingdom, and coauthors, will deliver a late-breaking poster presentation titled, "**RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers**"

American Heart Association's Scientific Sessions 2016 - New Orleans, November 12-16, 2016

November 14, 10:40 a.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "**Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism**"

November 14, 2:00 p.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "**Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)**"

The 28th Annual Piper Jaffray Healthcare Conference - New York, November 29-30, 2016

November 30, 8:30 a.m. EST - Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray

Copies of presentation materials and webcasts can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered.

About ARC-AAT

Arrowhead's ARC-AAT is being investigated for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that severely damages the liver and lungs of affected individuals. The mean estimated prevalence of AATD in the U.S. is 1 per 3000-5000, or approximately 100,000 patients. AATD is also an important cause of pediatric liver disease with an estimated prevalence in children of approximately 20,000 patients, and 50-80% likely to manifest liver disease during childhood. It is a rare disease that is frequently misdiagnosed or undiagnosed. ARC-AAT employs a novel unlocked nucleobase analog (UNA) containing RNAi trigger molecule designed for systemic delivery using the Dynamic Polyconjugate™ delivery system. ARC-AAT is highly effective at knocking down the alpha-1 antitrypsin (AAT) gene transcript and reducing the hepatic production of the mutant AAT (Z-AAT) protein in animal studies. Reduction of liver production of the inflammatory Z-AAT protein, which is believed to be the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease. ARC-AAT was granted orphan drug designation in both the United States and in Europe, the latter being held on Arrowhead's behalf by a local EU representative Pharma Gateway AB. Arrowhead is conducting a Phase 1 clinical study of ARC-AAT, with part A in healthy

volunteers (now complete) and part B in AATD patients, and a Phase 2 multiple dose study in AATD patients.

About ARC-F12

Arrowhead's RNAi-based candidate ARC-F12 is in preclinical development as a potential treatment for factor XII (F12) mediated diseases. Arrowhead sees clear unmet need in hereditary angioedema (HAE) and thromboembolic diseases. The biology of factor 12 as part of the coagulation cascade and the kinin-kallikrein system suggest that its reduction through RNAi may present opportunities in both disease areas. The company is currently conducting studies in order to advance ARC-F12 into clinical trials.

About ARC-LPA

Arrowhead's RNAi-based candidate ARC-LPA is in preclinical development as a potential treatment for cardiovascular diseases. ARC-LPA is designed to reduce production of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a). Lp (a) levels in humans are genetically defined and higher levels correlate with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead's first drug candidate to use a subcutaneously administered delivery construct.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005633/en/

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or

Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.